Yin Jie, Li Qi, Zhao Zheng, Yang Qing, Li Yu-Jie, Chen Ying, Wang Ya-Jie, Weng Xiao-Gang, Cai Wei-Yan, Zhu Xiao-Xin
School of Chinese Materia Medica,Capital Medical University Beijing 100069,China.
Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700,China.
Zhongguo Zhong Yao Za Zhi. 2019 Jan;44(2):235-241. doi: 10.19540/j.cnki.cjcmm.20181012.005.
In the background of the high incidence and high mortality of cardiovascular diseases,atherosclerosis is the main pathological feature of cardiovascular diseases and the core pathological basis for disease progression. In the evolution of atherosclerotic plaques,the rupture of unstable plaques,plaque shedding and formation of thrombosis are the most dangerous parts. In this process,the formation of plaque fibrosis is the core mechanism regulating plaque stability. Additionally,fibrosis reflects dynamic changes in the inflammatory processes and pathological changes. In view of the inflammation regulation and fibrosis regulation,this paper clarified the process of atherosclerotic plaque,explained the roles of relevant inflammatory cells and cytokines in plaque stability,and summed up drug researches related with stable plaque in recent years. In the future,improving the fibrosis will be a new idea for stabilizing plaque in atherosclerosis drug development.
在心血管疾病高发病率和高死亡率的背景下，动脉粥样硬化是心血管疾病的主要病理特征和疾病进展的核心病理基础。在动脉粥样硬化斑块的演变过程中，不稳定斑块的破裂、斑块脱落和血栓形成是最危险的部分。在此过程中，斑块纤维化的形成是调节斑块稳定性的核心机制。此外，纤维化反映了炎症过程和病理变化的动态变化。鉴于炎症调节和纤维化调节，本文阐明了动脉粥样硬化斑块的形成过程，解释了相关炎症细胞和细胞因子在斑块稳定性中的作用，并总结了近年来与稳定斑块相关的药物研究。未来，改善纤维化将是动脉粥样硬化药物研发中稳定斑块的新思路。
